Education
About Us
Working with TipRanks
Follow Us
Corcept Therapeutics Inc. (CORT)
NASDAQ:CORT
Earnings Data
Report Date
May 06, 2026TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.1Last Year’s EPS
0.17Same Quarter Last Year
Moderate Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented a mix of strong commercial momentum, robust clinical successes across multiple programs (notably ROSELLA and DAZALS), clear revenue growth and higher guidance, and resolved operational capacity with an improving commercial outlook. These positives are tempered by a significant regulatory setback for relacorilant in Cushing's syndrome, a Federal Circuit loss in the generic patent dispute, meaningful net income decline, and prior pharmacy-related supply disruptions. The pipeline and upcoming readouts provide multiple near-term catalysts, while regulatory and legal risks require attention.Company Guidance
Revenue Growth and 2026 Guidance
Full-year 2025 revenue was $761 million, up from $675 million in 2024 (≈+12.8%). Company provided 2026 revenue guidance of $900 million to $1 billion.
Strong Cash Position and Capital Actions
Cash and investments at December 31, 2025 were $532 million; 2025 included $245 million of share repurchases under the repurchase program.
Commercial Demand Expansion for Cushing's Products
Record number of new prescriptions in 2025: new prescriptions increased 61% year-over-year; tablets delivered increased 37% year-over-year despite capacity constraints, and monthly new patient starts improving after pharmacy transition.
CATALYST Trial — Diabetes Population Findings
Prevalence phase screened 1,000 uncontrolled diabetes patients and found 24% had hypercortisolism; treatment phase (n=136) showed Korlym reduced mean HbA1c by 1.47% vs 0.17% for placebo (absolute delta ≈1.30%), plus large decreases in weight and waist circumference.
ROSELLA Phase III — Positive Oncology Outcomes
In platinum-resistant ovarian cancer, relacorilant plus nab‑paclitaxel reduced risk of death by 35% (HR 0.65, p=0.0004), with median overall survival extended by 4.1 months and up to 8 months longer at the 75th percentile; met both dual primary endpoints and full data to be presented at SGO.
DAZALS (ALS) Phase II — Large Mortality Signal
In DAZALS, patients receiving 300 mg dazucorilant for 1 year showed an 84% reduction in risk of death vs placebo (p=0.0009); company initiating dose-titration work to address tolerability and plans pivotal trial later this year.
Ongoing Pipeline Momentum and Upcoming Readouts
MONARCH Phase IIb (MASH) fully enrolled (175 patients) with results expected by year-end; MOMENTUM results (resistant hypertension prevalence/treatment) to be announced next month; multiple oncology and combination studies ongoing with anticipated data through 2027.
Resolved Pharmacy Capacity Transition
Completed transition to new specialty pharmacy (Curant) with final patient files received; company reports improving fulfillment metrics, on track for a monthly record for new patient starts and greater capacity/scalability going forward.
CORT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CORT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 24, 2026 | $36.48 | $36.22 | -0.71% |
Nov 04, 2025 | $71.10 | $76.65 | +7.81% |
Jul 31, 2025 | $67.17 | $69.00 | +2.72% |
May 05, 2025 | $73.94 | $70.74 | -4.33% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Corcept Therapeutics Inc. (CORT) report earnings?
Corcept Therapeutics Inc. (CORT) is schdueled to report earning on May 06, 2026, TBA (Confirmed).
What is Corcept Therapeutics Inc. (CORT) earnings time?
Corcept Therapeutics Inc. (CORT) earnings time is at May 06, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CORT EPS forecast?
CORT EPS forecast for the fiscal quarter 2026 (Q1) is -0.1.